Replies to post #199657 on Biotech Values

[DewDiligence]

GILD’s Momelotinib goes 1-for-2 in SIMPLIFY/1-2 trials: #msg-126609986.

http://finance.yahoo.com/news/gilead-announces-top-line-results-211500046.html

The nominal success was in SIMPLIFY-1, where Momelotinib was non-inferior to Jakafi in JAK-naïve patients.

The failure was in SIMPLIFY-2, where Momelotinib was not superior to BAT (Best Available Therapy) in patients previously treated with—but not refractory to—Jakafi.

Momelotinib is the drug GILD picked up in the 2012 buyout of YMI (#msg-82377008).